Insulin Analogs
Also referenced as: Insulin analogs multiple, Insulin lispro, Insulin aspart, Insulin glargine, Insulin degludec
A family of engineered insulin medicines, not a single peptide or a research stack.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Multiple FDA-approved insulin products treat diabetes; approval, age criteria and formulation are product-specific. This overview is not an interchangeable dosing guide.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A family of engineered insulin medicines, not a single peptide or a research stack.
Multiple FDA-approved insulin products treat diabetes; approval, age criteria and formulation are product-specific. This overview is not an interchangeable dosing guide.
Lispro, aspart, glargine and degludec are distinct medicines. One product’s timing, formulation or label cannot be applied to the entire family.
Why It's Being Studied
- Diabetes
- Insulin replacement
- Glucose regulation
Mechanism of Action
Insulin-receptor activation changes glucose uptake and metabolic signalling; structural modifications alter absorption and duration.
Insulin-receptor activation changes glucose uptake and metabolic signalling; structural modifications alter absorption and duration. Lispro, aspart, glargine and degludec are distinct medicines. One product’s timing, formulation or label cannot be applied to the entire family.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Diabetes
- Insulin replacement
- Glucose regulation
- Product-specific approved injections
Evidence Summary
Multiple approved rapid- and long-acting products have established clinical efficacy in diabetes, with product-specific populations and pharmacokinetics.
Higher tiers carry more weight. Filled tiers have evidence for Insulin Analogs; tap to read it.
- Multiple approved rapid- and long-acting products have established clinical efficacy in diabetes, with product-specific populations and pharmacokinetics.
2 cited sources.
- Prescribing label2
Human clinical evidence
- Multiple approved rapid- and long-acting products have established clinical efficacy in diabetes, with product-specific populations and pharmacokinetics.
Reported Adverse Events in Research
- Severe hypoglycemia, hypokalemia and product-selection or concentration errors can be life-threatening.
Limitations of Current Evidence
- Lispro, aspart, glargine and degludec are distinct medicines. One product’s timing, formulation or label cannot be applied to the entire family.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Insulin Analogs | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Product-specific approved injections | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Insulin Analogs — prescribing label
- Prescribing label
insulin degludec prescribing sources